title: The protective effect of the recombinant 53-kDa protein of Trichinella spiralis on experimental colitis in mice.
abstract: BACKGROUND
  Helminth infection has been proven to reduce the severity of experimental inflammatory bowel disease (IBD). The excretory-secretory proteins of helminths play an important role in the process of immunomodulation.
  
  
  OBJECTIVE
  In the present study, we aimed to investigate the protective potential of recombinant Trichinella spiralis (TS) 53-kDa protein (rTsP53), a component of excretory-secretory proteins, on experimental colitis in mice.
  
  
  METHODS
  BALB/c mice were treated subcutaneously with 50 μg rTsP53 three times at an interval of 5 days. Colitis was induced by intrarectal administration of 5 mg trinitrobenzene sulfonic acid (TNBS). Disease activities and macroscopic and microscopic scores were evaluated. To determine immune response provoked by rTsP53, we measured specific IgG1 and IgG2a values against rTsP53 in sera of mice. We also detected cytokine profiles as well as the markers of alternatively activated macrophages (M2) in mice.
  
  
  RESULTS
  RTsP53 ameliorated significantly the disease activity index (DAI) as well as the macroscopic and microscopic scores. IgG1 but not IgG2a was the predominant specific antibody detected in the sera of immunized mice, indicating the potential of stimulating T-helper (Th) 2 bias response by rTsP3. Pre-treatment with rTsP53 decreased serum Th1 cytokines (TNF-a, IFN-γ) and elevated serum levels of serum Th2 cytokines (IL-4, IL-13); it also decreased colonic Th1 cytokines (TNF-α, IL-6) and colonic regulatory cytokines (IL-10, TGF-β1). RTsP53 increased colonic M2 markers, arginase-1 (Arg-1), and found in inflammatory zone 1 (FIZZ1), compared to mice without rTsP53 pretreatment.
  
  
  CONCLUSIONS
  RTsP53 is a potential protective agent for IBD.
authors.affiliation: Department of General Internal Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
authors.forename: Linlin
authors.initials: L
authors.lastname: Du
authors.forename: Hao
authors.initials: H
authors.lastname: Tang
authors.forename: Zhongfu
authors.initials: Z
authors.lastname: Ma
authors.forename: Jia
authors.initials: J
authors.lastname: Xu
authors.forename: Wenchao
authors.initials: W
authors.lastname: Gao
authors.forename: Jiajia
authors.initials: J
authors.lastname: Chen
authors.forename: Wenjia
authors.initials: W
authors.lastname: Gan
authors.forename: Zhaoping
authors.initials: Z
authors.lastname: Zhang
authors.forename: Xinbing
authors.initials: X
authors.lastname: Yu
authors.forename: Xingwang
authors.initials: X
authors.lastname: Zhou
authors.forename: Xuchu
authors.initials: X
authors.lastname: Hu
mesh_terms: D000818:Animals; D000947:Antigens, Helminth / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology*; D003106:Colon / Q000187:drug effects / Q000473:pathology; D016207:Cytokines / Q000097:blood; D004195:Disease Models, Animal; D015801:Helminth Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007074:Immunoglobulin G / Q000097:blood; D056747:Immunomodulation; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014302:Trinitrobenzenesulfonic Acid / Q000009:adverse effects / Q000494:pharmacology
chemical_list: D000947:Antigens, Helminth; D016207:Cytokines; D015801:Helminth Proteins; D007074:Immunoglobulin G; D011994:Recombinant Proteins; C097419:excretory-secretory antigen, Trichinella; D014302:Trinitrobenzenesulfonic Acid